THE COVID 19 SERVICES CATALYZE TRANSLATIONAL RESEARCH FINDINGS INTO PUBLIC HEALTH CHANGES TO ADDRESS THE NOVEL CORONAVIRUS PANDEMIC THROUGH IMPLEMENTA

COVID 19 服务促进公共卫生变革的转化研究成果，通过实施应对新型冠状病毒大流行

• 批准号: 10500611
• 负责人: LEONARD FREEDMAN
• 金额: $ 61.29万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-31 至 2021-08-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10500611
• 关键词: ACE2; Address; Biological; Biological Sciences; COVID-19; COVID-19 assay; Client; Contracts; Crystallography; Laboratories; Ligands; Peptides; Production; Public Health; Research Activity; Research Personnel; Services; Translational Research; diagnostic assay; experience; novel coronavirus; pandemic disease; programs; research and development; scale up

Advanced BioScience Laboratories, Inc. (ABL) is a global contract manufacturing organization with experience in biologics R&D, scale-up, and production following current Good Manufacturing Practices (cGMP). ABL partners with our clients to support GMP manufacturing needs. Dr. Wlodawer, Chief of the Macromolecular Crystallography Laboratory with the NCI-Frederick is working on a project, Chimeric ACE2 Peptide Ligand for Diagnostic Assays of SARS-CoV-2, under the Intramural Targeted Anti-Covid19 (ITAC) Program, which provides supplementary support for COVID-19 research activities for intramural investigators

Advanced BioScience Laboratories, Inc. (ABL) 是一家全球合同制造组织，在遵循现行良好生产规范 (cGMP) 的生物制剂研发、放大和生产方面拥有丰富经验。 ABL 与我们的客户合作，支持 GMP 生产需求。 NCI-Frederick 的大分子晶体学实验室主任 Wlodawer 博士正在开展一个项目，即用于 SARS-CoV-2 诊断分析的嵌合 ACE2 肽配体，该项目属于壁内靶向抗 Covid19 (ITAC) 计划，该计划提供了补充为校内研究人员的 COVID-19 研究活动提供支持